Skip to main content

Table 2 The association of antiplatelet drugs with VAF for AVF

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author Design N (Control) Exposure Timing Outcome (duration) VAF development Number of Bleeding events (Control)
Gröntoft et al [71] Placebo-controlled 258 (124) Ticlopidine
250 mg 2× /day
Pre
AVF thrombosis (28 days) Equivalent risk
(12% vs. 19%, P = 0.101)
None
Dember et al [70] Placebo-controlled 877 (436) Clopidgrel
75 mg/day
(loading 300 mg)
Pre
AVF suitable for HD (150–180 days) Equivalent risk
(61.8% vs. 59.5%, RR 1.05, 95% CI 0.94–1.17, P = 0.40)
12
(13)
NS
Ghorbani et al [69] Placebo-controlled 93 (47) Clopidogrel
75 mg/day
Pre
Primary AVF failure (2 months) Lower risk
(21.6% vs. 5.2%, RR 0.72, 95% CI 0.41–1.01, P = 0.03)
None
Irish et al [68] Placebo-controlled 406 (203) Aspirin
100mg /day
Pre
Primary AVF failure (12 months) Equivalent risk
(45% vs. 43%, RR 1.05, 95% CI 0.84–1.31, P = 0.68)
10
(16)
NS
  1. VAF vascular access failure, AVF arteriovenous fistula, RR relative risk, CI confidential interval, NS not significant, NA not available, Pre pre-operative period